CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Capital Expenditures Incurred but Not yet Paid
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Capital Expenditures Incurred but Not yet Paid of $23.00 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-27 was $2.21M, a 25.91% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-28 was $20.80M, a 7.12% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-27 was $19.14M, a 84.53% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-27 was $1.64M, a 78.12% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $46.14M, a 6.97% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $43.14M, a 37.61% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $69.14M, a 21.98% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $88.61M, a 23.00% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-27 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $23.00M 10-Q · filed 2026-08-05 | $42.14M derived: sum of 3 quarters · filed 2026-08-05 | $43.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $20.80M 10-Q · filed 2026-05-07 | $39.94M derived: sum of 2 quarters · filed 2026-05-07 | $41.57M derived: sum of 3 quarters · filed 2026-05-07 | $44.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $20.78M derived: sum of 2 quarters · filed 2026-02-18 | $23.75M derived: sum of 3 quarters · filed 2026-08-05 | $46.14M 10-K · filed 2026-02-18 |
| 2025-09-27 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.61M derived: sum of 2 quarters · filed 2026-08-05 | $27.00M 10-Q · filed 2025-11-05 | $37.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $25.37M 10-Q · filed 2026-08-05 | $35.74M derived: sum of 3 quarters · filed 2026-08-05 | $43.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $22.39M 10-Q · filed 2026-05-07 | $32.76M derived: sum of 2 quarters · filed 2026-05-07 | $40.25M derived: sum of 3 quarters · filed 2026-05-07 | $41.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $17.86M derived: sum of 2 quarters · filed 2026-02-18 | $19.23M derived: sum of 3 quarters · filed 2026-02-18 | $43.14M 10-K · filed 2026-02-18 |
| 2024-09-28 | $7.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.85M derived: sum of 2 quarters · filed 2025-11-05 | $32.76M 10-Q · filed 2025-11-05 | $60.38M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $25.28M 10-Q · filed 2025-08-06 | $52.89M derived: sum of 3 quarters · filed 2026-02-18 | $46.57M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $23.91M 10-Q · filed 2025-05-07 | $51.52M derived: sum of 2 quarters · filed 2026-02-18 | $45.20M derived: sum of 3 quarters · filed 2026-02-18 | $49.93M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $27.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $21.29M derived: sum of 2 quarters · filed 2026-02-18 | $26.02M derived: sum of 3 quarters · filed 2026-02-18 | $69.14M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.59M derived: sum of 2 quarters · filed 2024-11-06 | $41.53M 10-Q · filed 2024-11-06 | $78.37M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | $4.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $47.85M 10-Q · filed 2024-08-07 | $84.69M derived: sum of 3 quarters · filed 2025-02-19 | $84.69M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | $43.12M 10-Q · filed 2024-05-09 | $79.96M derived: sum of 2 quarters · filed 2025-02-19 | $79.95M derived: sum of 3 quarters · filed 2025-02-19 | $72.73M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $36.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $36.84M derived: sum of 2 quarters · filed 2025-02-19 | $29.62M derived: sum of 3 quarters · filed 2025-02-19 | $88.61M 10-K · filed 2025-02-19 |
| 2022-09-24 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$7.22M derived: sum of 2 quarters · filed 2023-11-08 | $51.77M 10-Q · filed 2023-11-08 | |
| 2022-06-25 | -$7.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $51.78M 10-Q · filed 2023-08-09 | ||
| 2022-03-26 | $58.99M 10-Q · filed 2023-05-11 | |||
| 2021-12-25 | $72.04M 10-K · filed 2024-02-14 | |||
| 2020-12-26 | $25.61M 10-K · filed 2023-02-22 | |||
| 2019-12-28 | $21.45M 10-K · filed 2022-02-16 | |||
| 2018-12-29 | $18.21M 10-K · filed 2021-02-17 | |||
| 2017-12-30 | $38.20M 10-K · filed 2020-02-11 | |||
| 2016-12-31 | $5.33M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $6.72M 10-K · filed 2018-02-13 | |||
| 2014-12-27 | $4.36M 10-K · filed 2017-02-14 | |||
| 2013-12-28 | $6.96M 10-K · filed 2016-02-12 | |||
| 2012-12-29 | $2.78M 10-K · filed 2015-02-17 | |||
| 2011-12-31 | $5.30M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |